Updates

Eris Lifesciences Limited has released a corporate presentation highlighting its robust business performance and strategic growth. The company has secured a position among the Top-20 Indian pharmas within 20 years, with 80% of revenue from super-specialty segments. It holds leading market shares in anti-diabetes therapy and insulins, and has seen a strong start with its Gx Semaglutide brand. The presentation also emphasizes successful leveraged acquisitions to enter high-value therapies and significant growth potential in its international business.